GlassScriptPhysician profile
Gabriel Mccoy
NPI 1114289519
$4,122.04
in general payments reported to CMS, 2019-2025
50 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $30.25 · 2021: $42.21 · 2022: $698 · 2023: $1,051 · 2024: $1,121 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,351.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $599.10 | 2022-2025 | |
| Pfizer INC. | $317.40 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $271.00 | 2023-2025 | Onivyde, Somatuline Depot |
| Seagen INC. | $229.90 | 2022-2023 | Tukysa, Padcev |
| Glaxosmithkline, LLC. | $219.97 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| E.R. Squibb & Sons, L.L.C. | $218.21 | 2022-2025 | Opdivo |
| Incyte Corporation | $192.95 | 2021-2025 | Jakafi, Pemazyre, Monjuvi |
| Genentech USA, INC. | $176.35 | 2022-2025 | Alecensa, Tecentriq, Rozlytrek |
| Astrazeneca Pharmaceuticals LP | $158.28 | 2020-2025 | Enhertu, Lynparza, Imfinzi |
| Merck Sharp & Dohme LLC | $138.59 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $105.66 | 2022-2025 | Rybrevant, Imbruvica, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $103.07 | 2022-2025 | Iclusig, Fruzaqla |
| Eisai INC. | $94.73 | 2022-2024 | |
| Emd Serono, INC. | $92.59 | 2023-2025 | Tepmetko |
| Celgene Corporation | $82.23 | 2022-2024 | Reblozyl |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Mccoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.